| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | CGP-60474 | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |